Annual Accounts Payable
$2.40 M
-$179.00 K-6.95%
December 31, 2023
Summary
- As of February 8, 2025, AVTE annual accounts payable is $2.40 million, with the most recent change of -$179.00 thousand (-6.95%) on December 31, 2023.
- During the last 3 years, AVTE annual accounts payable has risen by +$1.78 million (+287.70%).
- AVTE annual accounts payable is now -6.95% below its all-time high of $2.58 million, reached on December 31, 2022.
Performance
AVTE Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Payable
$908.00 K
-$3.27 M-78.27%
September 30, 2024
Summary
- As of February 8, 2025, AVTE quarterly accounts payable is $908.00 thousand, with the most recent change of -$3.27 million (-78.27%) on September 30, 2024.
- Over the past year, AVTE quarterly accounts payable has dropped by -$1.49 million (-62.10%).
- AVTE quarterly accounts payable is now -83.58% below its all-time high of $5.53 million, reached on June 30, 2023.
Performance
AVTE Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Payable Formula
Accounts Payable = Beginning Accounts Payable + Purchases on Credit − Payments to Suppliers
AVTE Accounts Payable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -7.0% | -62.1% |
| 3 y3 years | +287.7% | -62.1% |
| 5 y5 years | +342.1% | -62.1% |
AVTE Accounts Payable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -7.0% | +98.3% | -83.6% | at low |
| 5 y | 5-year | -7.0% | +342.1% | -83.6% | +46.9% |
| alltime | all time | -7.0% | +342.1% | -83.6% | +46.9% |
Aerovate Therapeutics Accounts Payable History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $908.00 K(-78.3%) |
| Jun 2024 | - | $4.18 M(+26.1%) |
| Mar 2024 | - | $3.31 M(+38.3%) |
| Dec 2023 | $2.40 M(-7.0%) | $2.40 M(-31.6%) |
| Sep 2023 | - | $3.50 M(-36.6%) |
| Jun 2023 | - | $5.53 M(+17.0%) |
| Mar 2023 | - | $4.73 M(+83.5%) |
| Dec 2022 | $2.58 M | $2.58 M(-43.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2022 | - | $4.54 M(+119.6%) |
| Jun 2022 | - | $2.07 M(-27.8%) |
| Mar 2022 | - | $2.86 M(+137.0%) |
| Dec 2021 | $1.21 M(+95.5%) | $1.21 M(-52.7%) |
| Sep 2021 | - | $2.56 M(-16.0%) |
| Jun 2021 | - | $3.04 M(+96.3%) |
| Mar 2021 | - | $1.55 M(+150.8%) |
| Dec 2020 | $618.00 K(+14.0%) | $618.00 K |
| Dec 2019 | $542.00 K | - |
FAQ
- What is Aerovate Therapeutics annual accounts payable?
- What is the all time high annual accounts payable for Aerovate Therapeutics?
- What is Aerovate Therapeutics annual accounts payable year-on-year change?
- What is Aerovate Therapeutics quarterly accounts payable?
- What is the all time high quarterly accounts payable for Aerovate Therapeutics?
- What is Aerovate Therapeutics quarterly accounts payable year-on-year change?
What is Aerovate Therapeutics annual accounts payable?
The current annual accounts payable of AVTE is $2.40 M
What is the all time high annual accounts payable for Aerovate Therapeutics?
Aerovate Therapeutics all-time high annual accounts payable is $2.58 M
What is Aerovate Therapeutics annual accounts payable year-on-year change?
Over the past year, AVTE annual accounts payable has changed by -$179.00 K (-6.95%)
What is Aerovate Therapeutics quarterly accounts payable?
The current quarterly accounts payable of AVTE is $908.00 K
What is the all time high quarterly accounts payable for Aerovate Therapeutics?
Aerovate Therapeutics all-time high quarterly accounts payable is $5.53 M
What is Aerovate Therapeutics quarterly accounts payable year-on-year change?
Over the past year, AVTE quarterly accounts payable has changed by -$1.49 M (-62.10%)